Los Angeles Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
MCMU
Los Angeles Capital Management's RXRX Position: Q2 2026 in Review
Los Angeles Capital Management reduced its Recursion Pharmaceuticals (RXRX) stake by 18% in Q2 2026, selling an estimated $206K and leaving 273,720 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #744.
Los Angeles Capital Management first reported a position in RXRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $1.03M in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- Los Angeles Capital Management held 273,720 shares of Recursion Pharmaceuticals worth $1M as of Q2 2026.
- Los Angeles Capital Management sold 61,904 Recursion Pharmaceuticals shares in Q2 2026, an estimated $206K.
- Recursion Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #744 holding.
- Los Angeles Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
- Los Angeles Capital Management's Recursion Pharmaceuticals position peaked at $1.03M in Q1 2026.
- 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.